Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Skin Diseases, Papulosquamous 1Skin Diseases 1Psoriasis 1Plaque, Amyloid 1Lymphoma, Follicular 1Bronchiolitis Obliterans Syndrome 1Arthritis, Rheumatoid 1

Interventions

tofacitinib 7ibrutinib 4Rituximab 4Imatinib Mesylate 3ruxolitinib 2ofatumumab 2obinutuzumab 2nilotinib 2bosutinib 2sodium luminolate 1posaconazole 1pegfilgrastim 1montelukast 1ixekizumab 1fludarabine 1canakinumab 1belumosudil 1baricitinib 1axatilimab 1Voriconazole 1Tomography, X-Ray Computed 1Sofosbuvir 1Sirolimus 1Ribavirin 1Respiratory Function Tests 1Proto-Oncogene Proteins c-raf 1Prednisone 1Photopheresis 1Pentostatin 1Mycophenolic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bronchiolitis Obliterans Syndrome × baricitinib × Clear all
NCT01490632 2019-09-27

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Eli Lilly and Company

Phase 2 Completed
271 enrolled 32 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous, Plaque, Amyloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡